Why CVS Health Shares Are Rising

CVS Health Corp (NYSE: CVS) shares are trading higher by 2.43% to $74.06 Wednesday morning. Shares of healthcare stocks are trading higher in sympathy with Elevance Health, which reported better-than-expected second-quarter financial results and raised guidance.

CVS Health Corp (NYSE:CVS) shares are trading higher by 2.43% to $74.06 Wednesday morning. Shares of healthcare stocks are trading higher in sympathy with Elevance Health, which reported better-than-expected second-quarter financial results and raised guidance.

What Happened?

Elevance Health has announced adjusted second-quarter EPS of $9.04, reflecting a 13.4% year-over-year increase and surpassing the consensus estimate of $8.80. Furthermore, the company experienced a 13% growth in revenue, reaching $43.67 billion, exceeding the projected figure of $41.50 billion.

This increase can be attributed to premium rate increases in the Health Benefits business, higher premium revenue resulting from membership growth in Medicaid and Medicare, as well as the expansion of pharmacy product revenue through the acquisition of BioPlus in Q1 2023 and the growth of external pharmacy members served by CarelonRxRead More

According to data from Benzinga Pro, CVS has a 52-week high of $107.26 and a 52-week low of $66.34.

Total
0
Shares
Related Posts
Read More

US Healthcare Landlord Medical Properties Trust’s Largest Tenant Steward Health Goes Bankrupt, Sparks Regulatory Concerns

Amid Chapter 11 bankruptcy, Steward Health Care, Medical Properties Trust's tenant, faces financial turmoil. State regulators scrutinize its 30 hospitals, grappling with incidents like bat evacuations, unpaid nurses, and equipment shortages. Steward's reliance on MPW for a $300 million loan raises eyebrows, as stakeholders navigate complex ties amid regulatory interventions.

MPW

Read More

Apparel Company VF’s Fortune Will Not Turn For The Better, Says Analyst

Wedbush analyst Tom Nikic reiterated a Neutral rating on VF Corp shares, lowering the price target from $15.5 to $13. Nikic's checks suggest continued business challenges, with Vans being a significant issue. The analyst cut FY24-26 EPS forecasts and noted declining e-commerce traffic for The North Face and Vans. The company's highly-levered balance sheet adds further pressure.

VFC